Eli Lilly and Company (LLY):
Eli Lilly and Company (LLY) ended its previous trading session at $88.91 with the Gain of 1.54%. The company’s market cap is $95.53 Billion, and the average volume is $3.69 Million. The 52-Week High range of the stock is $89.09, while the 52-week low range is $73.69. The Price to Sales (P/S) of the stock is 4.09, while P/B (Price to Book) stands at 6.41. When we look at the Volatility of the company, Week Volatility is at 0.96% whereas Month Volatility is at 1.20%.
For the ongoing Fiscal Quarter, 13 analysts have an average earnings forecast of $1.3 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $1.24, while the High earnings estimate is $1.38.Comparatively, EPS for the same quarter last year was $1.11.
According to 11 analysts, the Average Revenue Estimate for the current Fiscal quarter is $5.97 Billion and the Low Revenue estimate is $5.63 Billion, while the High Revenue estimate is $6.14 Billion.
Eli Lilly and Company (LLY) analysts on average have given a price target of $91.26 on LLY stock.
According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 2.3 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.
Novo Nordisk A/S (NVO):
Novo Nordisk A/S (NVO) shares Jumped 2.17% and ended the day at $49.9. Its 52-week high and low range is between $58.37 and $41.03. The company’s outstanding shares are 1.9 Billion. The volume of the company in the last trading session was 1.47 Million. The stock has a market cap of 94.59 Billion. The Stock shows P/E value of 20.24 and Forward P/E of 19.62.
According to Finviz reported data, The SMA20 of the stock is at 7.39%, SMA50 is 5.66 percent, while SMA200 is -0.47%. The stock is currently has its Return on Assets (ROA) value of 39.6 Percent. The Return on Investment and Return on Equity (ROE) values are 74.6 percent and 81.8 percent, respectively.
The company’s ATR (Average True Range) is 0.75. The Weekly Volatility is 0.90% and the Monthly Volatility is 1.15%.
When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Novo Nordisk A/S (NVO) analysts on average have given a price target of $91.26 on NVO stock.
Novo Nordisk A/S’s Average Earnings Estimate for the current quarter is $0.62, according to consensus of 1 analysts. The low EPS estimate is $0.62, while the high EPS estimate is $0.62.
Average Revenue Estimate of the company for the current Fiscal Quarter is $4.26 Billion, according to consensus of 1 analysts. The higher end of the revenue estimate is $4.26 Billion and the lower end is $4.26 Billion.